David M. Hilbert - Publications

1983-1987 Immunology Graduate Group University of Pennsylvania Perelman School of Medicine 
 1987-1995 Laboratory of Genetics NIH, NCI 
 1995-2005 Research and Development Human Genome Sciences 
 2010- Founder, VP for research Cellective Therapeutics 

17/18 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2013 LaFleur DW, Abramyan D, Kanakaraj P, Smith RG, Shah RR, Wang G, Yao XT, Kankanala S, Boyd E, Zaritskaya L, Nam V, Puffer BA, Buasen P, Kaithamana S, Burnette AF, ... ... Hilbert DM, et al. Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides. Mabs. 5: 208-18. PMID 23575268 DOI: 10.4161/mabs.23043  0.68
2012 Kanakaraj P, Puffer BA, Yao XT, Kankanala S, Boyd E, Shah RR, Wang G, Patel D, Krishnamurthy R, Kaithamana S, Smith RG, LaFleur DW, Barbas CF, Hilbert DM, Kiener PA, et al. Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. Mabs. 4: 600-13. PMID 22864384 DOI: 10.4161/mabs.21227  0.68
2012 Stohl W, Hilbert DM. The discovery and development of belimumab: the anti-BLyS-lupus connection. Nature Biotechnology. 30: 69-77. PMID 22231104 DOI: 10.1038/nbt.2076  0.68
2008 Woodland RT, Fox CJ, Schmidt MR, Hammerman PS, Opferman JT, Korsmeyer SJ, Hilbert DM, Thompson CB. Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival. Blood. 111: 750-60. PMID 17942753 DOI: 10.1182/blood-2007-03-077222  0.68
2006 Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis and Rheumatism. 54: 723-32. PMID 16508933 DOI: 10.1002/art.21650  0.68
2006 Collins CE, Gavin AL, Migone TS, Hilbert DM, Nemazee D, Stohl W. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Research & Therapy. 8: R6. PMID 16356193 DOI: 10.1186/ar1855  0.68
2005 Fleming TJ, Sachdeva M, Delic M, Beltzer J, Wescott CR, Devlin M, Lander RC, Nixon AE, Roschke V, Hilbert DM, Sexton DJ. Discovery of high-affinity peptide binders to BLyS by phage display. Journal of Molecular Recognition : Jmr. 18: 94-102. PMID 15382264 DOI: 10.1002/jmr.722  0.68
2003 Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Xu D, Roschke V, Wu Y, Baker KP, Hilbert DM. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis and Rheumatism. 48: 3475-86. PMID 14673998 DOI: 10.1002/art.11354  0.68
2003 Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, Lappin PB, Riccobene T, Abramian D, Sekut L, Sturm B, Poortman C, Minter RR, Dobson CL, Williams E, ... ... Hilbert DM, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis and Rheumatism. 48: 3253-65. PMID 14613291 DOI: 10.1002/art.11299  0.68
2003 Stewart DM, McAvoy MJ, Hilbert DM, Nelson DL. B lymphocytes from individuals with common variable immunodeficiency respond to B lymphocyte stimulator (BLyS protein) in vitro. Clinical Immunology (Orlando, Fla.). 109: 137-43. PMID 14597212 DOI: 10.1016/S1521-6616(03)00215-8  0.68
2003 Tan SM, Xu D, Roschke V, Perry JW, Arkfeld DG, Ehresmann GR, Migone TS, Hilbert DM, Stohl W. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis and Rheumatism. 48: 982-92. PMID 12687540 DOI: 10.1002/art.10860  0.68
2002 Nardelli B, Moore PA, Li Y, Hilbert DM. B lymphocyte stimulator (BLyS): a therapeutic trichotomy for the treatment of B lymphocyte diseases. Leukemia & Lymphoma. 43: 1367-73. PMID 12389615 DOI: 10.1080/10428190290033297  0.68
2002 Roschke V, Sosnovtseva S, Ward CD, Hong JS, Smith R, Albert V, Stohl W, Baker KP, Ullrich S, Nardelli B, Hilbert DM, Migone TS. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. Journal of Immunology (Baltimore, Md. : 1950). 169: 4314-21. PMID 12370363  0.68
2002 Stohl W, Cheema GS, Briggs WS, Xu D, Sosnovtseva S, Roschke V, Ferrara DE, Labat K, Sattler FR, Pierangeli SS, Hilbert DM. B lymphocyte stimulator protein-associated increase in circulating autoantibody levels may require CD4+ T cells: lessons from HIV-infected patients. Clinical Immunology (Orlando, Fla.). 104: 115-22. PMID 12165272 DOI: 10.1006/clim.2002.5238  0.68
2002 Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, Cerutti A. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nature Immunology. 3: 822-9. PMID 12154359 DOI: 10.1038/ni829  0.68
2002 Hsu BL, Harless SM, Lindsley RC, Hilbert DM, Cancro MP. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. Journal of Immunology (Baltimore, Md. : 1950). 168: 5993-6. PMID 12055205  0.68
2002 Briones J, Timmerman JM, Hilbert DM, Levy R. BLyS and BLyS receptor expression in non-Hodgkin's lymphoma. Experimental Hematology. 30: 135-41. PMID 11823048 DOI: 10.1016/S0301-472X(01)00774-3  0.68
Low-probability matches
2019 Qin H, Edwards JP, Zaritskaya L, Gupta A, Mu CJ, Fry TJ, Hilbert DM, LaFleur DW. Chimeric Antigen Receptors Incorporating D Domains Targeting CD123 Direct Potent Mono- and Bi-specific Antitumor Activity of T Cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 31043341 DOI: 10.1016/j.ymthe.2019.04.010  0.01
Hide low-probability matches.